| Human immunodeficiency virus I infection
Descovy for PrEP vs Genvoya
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Descovy vs Genvoya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGenvoya has a higher rate of injection site reactions vs Descovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Genvoya but not Descovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Descovy
Genvoya
At A Glance
Oral
Daily
NRTI combination
Oral
Once daily
Fixed-dose combination: INSTI + CYP3A inhibitor + NRTIs
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection Adults and pediatric patients >=35 kg: one 200 mg/25 mg tablet once daily with or without food; pediatric patients 25 to <35 kg: one 200 mg/25 mg tablet once daily; 14 to <25 kg: one 120 mg/15 mg tablet once daily (with other antiretrovirals including DRV+COBI but not other PI/ritonavir or PI/cobicistat combinations); not recommended with eGFR 15-30 mL/min or <15 mL/min without chronic hemodialysis.
HIV-1 PrEP One 200 mg/25 mg tablet once daily orally with or without food in adults and adolescents >=35 kg with eGFR >=30 mL/min, or adults with eGFR <15 mL/min on chronic hemodialysis (dose after hemodialysis); not recommended with eGFR 15-30 mL/min or <15 mL/min without hemodialysis.
Human immunodeficiency virus I infection One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) orally once daily with food in patients weighing at least 25 kg with creatinine clearance >=30 mL/min, or adults with creatinine clearance <15 mL/min receiving chronic hemodialysis (administer after hemodialysis on dialysis days).
Contraindications
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
- Alfuzosin
- Carbamazepine
- Phenobarbital
- Phenytoin
- Rifampin
- Lurasidone
- Pimozide
- Dihydroergotamine
- Ergotamine
- Methylergonovine
- St. John's wort
- Lomitapide
- Lovastatin
- Simvastatin
- Sildenafil for pulmonary arterial hypertension
- Triazolam
- Orally administered midazolam
Adverse Reactions
Most common (>=10%) Nausea (in antiretroviral treatment-naive adults with HIV-1 receiving FTC+TAF with EVG+COBI)
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=5%) Nausea, diarrhea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
Dual HIV NRTI combination; emtricitabine (FTC) and tenofovir alafenamide (TAF) each inhibit HIV-1 reverse transcriptase via nucleotide analog chain termination after intracellular phosphorylation, with TAF serving as a prodrug converted intracellularly to tenofovir and then to the active metabolite tenofovir diphosphate.
GENVOYA is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor that prevents HIV-1 DNA integration into host genomic DNA), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine (a nucleoside reverse transcriptase inhibitor that causes viral DNA chain termination), and tenofovir alafenamide (a prodrug converted to tenofovir diphosphate, which inhibits reverse transcriptase through DNA chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Descovy
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (11/12)
Genvoya
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Descovy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Genvoya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Descovy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Genvoya
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DescovyView full Descovy profile
GenvoyaView full Genvoya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.